Share on StockTwits

Enanta Pharmaceuticals (NASDAQ:ENTA) is scheduled to post its quarterly earnings results on Monday, May 12th. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($0.30) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.15) by $0.15. The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $1.41 million. On average, analysts expect Enanta Pharmaceuticals to post $1.35 EPS for the current fiscal year and $6.92 EPS for the next fiscal year.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) opened at 34.41 on Friday. Enanta Pharmaceuticals has a 52 week low of $16.18 and a 52 week high of $43.73. The stock has a 50-day moving average of $36.59 and a 200-day moving average of $32.11. The company’s market cap is $631.9 million.

ENTA has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Enanta Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, April 16th. They now have a $43.80 price target on the stock. On the ratings front, analysts at Leerink Swann raised their price target on shares of Enanta Pharmaceuticals from $29.00 to $45.00 in a research note on Monday, March 10th. Finally, analysts at JMP Securities raised their price target on shares of Enanta Pharmaceuticals to $50.00 in a research note on Tuesday, February 18th. They now have an “outperform” rating on the stock. Three analysts have rated the stock with a buy rating, Enanta Pharmaceuticals has an average rating of “Buy” and an average price target of $44.56.

In other Enanta Pharmaceuticals news, Insider Yat Sun Or sold 5,000 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $36.98, for a total value of $184,900.00. Following the completion of the transaction, the insider now directly owns 184,078 shares of the company’s stock, valued at approximately $6,807,204. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.